A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
OnKure Therapeutics, Inc. (“OnKure”, “we”, “us” or the “Company”) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines that target biologically validated drivers of cancers underserved by available therapies. Using a structure- and computational chemistry-driven drug design platform, we are committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. By improving selectivity for the oncogenic and mutated form of these cancer-driver proteins, we aim to discover and develop drugs with improved safety and efficacy by sparing toxicity that arises from non-selective inhibition of the non-mutated (or wild-type) version of the protein.
| Metric | TTM | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | 0 | - | 1.6M |
| Net Income | -81M | -53M | - |
| EPS | $-13.46 | $-15.28 | $-124.41 |
| Free Cash Flow | -61M | -51M | -35M |
| ROIC | -89.6% | -50.7% | - |
| Gross Margin | - | - | - |
| Debt/Equity | 0.00 | 0.11 | -0.08 |
| Dividends/Share | $0.00 | - | - |
| Operating Income | -83M | -54M | -37M |
| Operating Margin | 0.0% | - | -2275.7% |
| ROE | -122.2% | -5304.4% | - |
| Shares Outstanding | 13M | 13M | 13M |
| Metric | |||
|---|---|---|---|
| Income Statement | |||
| Revenue | 1.6M | N/A | 0 |
| Gross Margin | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A |
| EBIT | -37M | -54M | -83M |
| Op. Margin | -2275.7% | N/A | 0.0% |
| Net Income | N/A | -53M | -81M |
| Net Margin | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 |
| Returns on Capital | |||
| ROIC | N/A | -50.7% | -89.6% |
| ROE | N/A | -5304.4% | -122.2% |
| ROA | N/A | -69.9% | -111.5% |
| Cash Flow | |||
| Op. Cash Flow | -35M | -51M | -61M |
| Free Cash Flow | -35M | -51M | -61M |
| Owner Earnings | -35M | -56M | -66M |
| CapEx | 246K | 52K | 87K |
| Maint. CapEx | 417K | 459K | 459K |
| Growth CapEx | 0 | 0 | 0 |
| D&A | 417K | 459K | 459K |
| CapEx/OCF | N/A | N/A | 0.0% |
| Capital Allocation | |||
| Dividends Paid | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | 0.0% |
| Stock-Based Comp | 199K | 4.5M | 4.5M |
| Debt Repayment | 0 | 0 | 0 |
| Balance Sheet | |||
| Net Debt | N/A | N/A | -70M |
| Cash & Equiv. | N/A | N/A | 70M |
| Long-Term Debt | N/A | N/A | N/A |
| Debt/Equity | -0.08 | 0.11 | 0.00 |
| Interest Coverage | N/A | N/A | N/A |
| Equity | -102M | 104M | 66M |
| Total Assets | 36M | 115M | 73M |
| Total Liabilities | 7.8M | 11M | 6.4M |
| Intangibles | N/A | N/A | N/A |
| Retained Earnings | -102M | -155M | -155M |
| Working Capital | 26M | 102M | 102M |
| Current Assets | 34M | 113M | 113M |
| Current Liabilities | 7.3M | 11M | 11M |
| Per Share Data | |||
| EPS | -124.41 | -15.28 | -13.46 |
| Owner EPS | -2.62 | -4.18 | -5.16 |
| Book Value | -7.58 | 7.73 | 5.16 |
| Cash Flow/Share | -2.57 | -3.80 | -6.28 |
| Dividends/Share | N/A | N/A | 0.00 |
| Shares Out. | 13.4M | 13.4M | 12.9M |
| Valuation | |||
| P/E Ratio | N/A | N/A | -0.3 |
| P/FCF | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A |
| Price/Book | N/A | 1.1 | 0.9 |
| Price/Sales | 509.3 | N/A | N/A |
| FCF Yield | -16.2% | -46.7% | -103.7% |
| Market Cap | 215M | 110M | 59M |
| Avg. Price | 61.52 | 15.89 | 4.61 |
| Year-End Price | 16.00 | 8.16 | 4.61 |
OnKure Therapeutics, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
OnKure Therapeutics, Inc. (OKUR) has a 5-year average return on invested capital (ROIC) of -50.7%. This is below average and may indicate limited pricing power.
OnKure Therapeutics, Inc. (OKUR) has a market capitalization of $59M. It is classified as a small-cap stock.
OnKure Therapeutics, Inc. (OKUR) does not currently pay a regular dividend.
OnKure Therapeutics, Inc. (OKUR) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
OnKure Therapeutics, Inc. (OKUR) generated $-51 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
OnKure Therapeutics, Inc. (OKUR) has a debt-to-equity ratio of 0.11. This indicates a conservatively financed balance sheet.
OnKure Therapeutics, Inc. (OKUR) reported earnings per share (EPS) of $-15.28 in its most recent fiscal year.
OnKure Therapeutics, Inc. (OKUR) has a return on equity (ROE) of -5304.4%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 2 years of financial data for OnKure Therapeutics, Inc. (OKUR), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
OnKure Therapeutics, Inc. (OKUR) has a book value per share of $7.73, based on its most recent annual SEC filing.